US 11,672,799 B2
1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions
Atwood Kim Cheung, Arlington, MA (US); Natalie Dales, Arlington, MA (US); and Timothy Brian Hurley, Boston, MA (US)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Jan. 28, 2019, as Appl. No. 16/259,441.
Application 16/259,441 is a continuation of application No. 16/030,139, filed on Jul. 9, 2018, abandoned.
Application 16/030,139 is a continuation of application No. 14/909,052, abandoned, previously published as PCT/US2014/048984, filed on Jul. 30, 2014.
Claims priority of provisional application 61/860,388, filed on Jul. 31, 2013.
Prior Publication US 2019/0160062 A1, May 30, 2019
Int. Cl. A61K 31/501 (2006.01); C07D 401/14 (2006.01); C07D 401/04 (2006.01); A61K 31/502 (2006.01); A61K 31/517 (2006.01); C07D 487/10 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01); A61K 31/5377 (2006.01)
CPC A61K 31/501 (2013.01) [A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01)] 9 Claims
 
1. A compound according to Formula (IA), or salt thereof

OG Complex Work Unit Chemistry
wherein A is selected from the group consisting of:

OG Complex Work Unit Chemistry
wherein
u and v are each, independently, 0, 1, 2 or 3; and
each Raand Rb, are, independently, selected from cyano, halogen, hydroxy, C1-C4 alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C3-C7cycloalkyl, heterocyclyl, heteroaryl, heterocyclyl C1-C4alkyl, C1-C4alkyl aryl, C1-C4alkyl heterocyclyl, C1-C4alkyl heteroaryl, C1-C4alkoxy aryl, C1-C4alkoxy heterocyclyl, C1-C4alkoxy heteroaryl, and C1-C4alkoxy substituted with hydroxy, C1-C4 alkoxy, amino and mono-and di-C1-C4alkylamino; and
B is selected from the group consisting of:

OG Complex Work Unit Chemistry
wherein X is O or N(Me) or NH; and
R17 is hydrogen or methyl.